| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/ARCHPSYC.58.5.485 |
| P698 | PubMed publication ID | 11343529 |
| P2093 | author name string | Davidson JR | |
| van der Kolk BA | |||
| Rothbaum BO | |||
| Farfel GM | |||
| Sikes CR | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | post-traumatic stress disorder | Q202387 |
| sertraline | Q407617 | ||
| multicenter clinical trial | Q6934595 | ||
| placebo | Q269829 | ||
| P304 | page(s) | 485-492 | |
| P577 | publication date | 2001-05-01 | |
| P1433 | published in | JAMA Psychiatry | Q635830 |
| P1476 | title | Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder | |
| P478 | volume | 58 |
| Q35622791 | "Dwelling in the Past": The Role of Rumination in the Treatment of Posttraumatic Stress Disorder |
| Q37544896 | "How will it help me?" Reasons underlying treatment preferences between sertraline and prolonged exposure in posttraumatic stress disorder |
| Q38919158 | A Pilot Study of Neurofeedback for Chronic PTSD. |
| Q35418015 | A chinese herbal formula to improve general psychological status in posttraumatic stress disorder: a randomized placebo-controlled trial on sichuan earthquake survivors |
| Q35200059 | A diet enriched with curcumin impairs newly acquired and reactivated fear memories |
| Q38006441 | A pharmacotherapeutic approach to the management of chronic posttraumatic stress disorder |
| Q38374699 | A randomized controlled trial of ganaxolone in posttraumatic stress disorder |
| Q34309474 | A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). |
| Q45330756 | A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder |
| Q37641713 | Acute hemodynamic effects of a selective serotonin reuptake inhibitor in postural tachycardia syndrome: a randomized, crossover trial. |
| Q59339661 | Add-on Eye Movement Desensitization and Reprocessing (EMDR) Therapy for Adults with Post-traumatic Stress Disorder Who Failed to Respond to Initial Antidepressant Pharmacotherapy |
| Q48254554 | Advances and controversies in military posttraumatic stress disorder screening |
| Q44593401 | Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline |
| Q38240674 | Anticonvulsants to treat post-traumatic stress disorder |
| Q36946123 | Antiepileptic drugs for the treatment of post-traumatic stress disorder |
| Q35904830 | Antiepileptic drugs in the treatment of anxiety disorders: role in therapy |
| Q35561526 | Anxiety disorders in women |
| Q34232131 | Are PTSD treatment choices and treatment beliefs related to depression symptoms and depression-relevant treatment rationales? |
| Q28385622 | Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP) |
| Q37051182 | Assessing post-traumatic stress symptoms in a Latino prison population |
| Q45330630 | Assessment and treatment of combat-related PTSD in returning war veterans |
| Q45328979 | Attentional bias modification in Dutch veterans with posttraumatic stress disorder--a case series with a personalized treatment version |
| Q44551415 | Baclofen treatment for chronic posttraumatic stress disorder |
| Q90400310 | Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline |
| Q27009995 | Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders |
| Q36813518 | Changes in temporal attention inhibition following prolonged exposure and sertraline in the treatment of PTSD |
| Q92177870 | Clinical Therapeutic Strategy and Neuronal Mechanism Underlying Post-Traumatic Stress Disorder (PTSD) |
| Q35680402 | Comorbidities in chronic neuropathic pain |
| Q95840681 | Comparative Efficacy and Acceptability of Pharmaceutical Management for Adults With Post-Traumatic Stress Disorder: A Systematic Review and Meta-Analysis |
| Q88096127 | Comparison between paroxetine and behaviour therapy in patients with posttraumatic stress disorder (PTSD): A pilot study |
| Q34547654 | Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder |
| Q34436812 | Comparison of the effectiveness of trauma-focused cognitive behavioral therapy and paroxetine treatment in PTSD patients: design of a randomized controlled trial |
| Q38859526 | Concurrent Treatment of Substance Use and PTSD. |
| Q38631796 | Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder |
| Q30587237 | Deep brain stimulation of the basolateral amygdala for treatment-refractory combat post-traumatic stress disorder (PTSD): study protocol for a pilot randomized controlled trial with blinded, staggered onset of stimulation |
| Q35219862 | Diagnosis and management of sleep disorders in posttraumatic stress disorder:a review of the literature |
| Q37610143 | Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis |
| Q33972544 | Differential effects of sertraline in a predator exposure animal model of post-traumatic stress disorder |
| Q36604308 | Disability and quality of life in post-traumatic stress disorder: impact of drug treatment |
| Q40756390 | Dissociation predicts treatment response in eye-movement desensitization and reprocessing for posttraumatic stress disorder |
| Q36214405 | Dosage, effectiveness, and safety of sertraline treatment for posttraumatic stress disorder in a Japanese clinical setting: a retrospective study |
| Q38925577 | Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study |
| Q46670491 | Effect of sertraline on glucocorticoid sensitivity of mononuclear leukocytes in post-traumatic stress disorder |
| Q26824470 | Effects of sex and gender on adaptation to space: behavioral health |
| Q35110297 | Escitalopram in the prevention of posttraumatic stress disorder: a pilot randomized controlled trial |
| Q30434663 | Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial |
| Q45216936 | Evidence-based pharmacotherapy for mood and anxiety disorders with concurrent alcoholism. |
| Q37907415 | Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). |
| Q34636674 | Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder |
| Q73040498 | Factor analysis of treatment response in posttraumatic stress disorder |
| Q36824681 | Functional impairment in adults with past posttraumatic stress disorder: findings from primary care |
| Q30428666 | Ganaxolone improves behavioral deficits in a mouse model of post-traumatic stress disorder |
| Q91619284 | Individual prediction of psychotherapy outcome in posttraumatic stress disorder using neuroimaging data |
| Q57772653 | Interventions for Individuals After Mass Violence and Disaster |
| Q35108839 | Interventions for trauma‐related emotional disturbances in adult victims of crime |
| Q47609382 | Investigating the role of nisoldipine in foot-shock-induced post-traumatic stress disorder in mice. |
| Q33734532 | Long-Term Sertraline Intake Reverses the Behavioral Changes Induced by Prenatal Stress in Rats in a Sex-Dependent Way. |
| Q34531930 | Long-term pharmacotherapy for post-traumatic stress disorder |
| Q44412271 | Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study |
| Q34749176 | Managing acute stress response to major trauma |
| Q89819832 | Mechanisms of Shared Vulnerability to Post-traumatic Stress Disorder and Substance Use Disorders |
| Q45331438 | Medication adherence and its effect on relapse among patients discharged from a Veterans Affairs posttraumatic stress disorder treatment program |
| Q39274920 | Mental health response to acute stress following wilderness disaster |
| Q38716352 | Minimal Clinically Important Differences (MCID) in Assessing Outcomes of Post-Traumatic Stress Disorder |
| Q34648267 | Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial |
| Q34906902 | Neural correlates of inhibition and contextual cue processing related to treatment response in PTSD. |
| Q59791313 | Neuroscience Informed Prolonged Exposure Practice: Increasing Efficiency and Efficacy Through Mechanisms |
| Q34990027 | New directions in the pharmacotherapy of posttraumatic stress disorder |
| Q35859824 | New trends in the treatment of anxiety disorders. |
| Q34533757 | Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports. |
| Q36002473 | PSYCHOTHERAPY VERSUS PHARMACOTHERAPY FOR POSTTRAUMATIC STRESS DISORDER: SYSTEMIC REVIEW AND META-ANALYSES TO DETERMINE FIRST-LINE TREATMENTS. |
| Q28070159 | PTSD: from neurobiology to pharmacological treatments |
| Q36734128 | Pharmacologic management of posttraumatic stress disorder |
| Q24633256 | Pharmacological treatment of PTSD - established and new approaches |
| Q38726468 | Pharmacology for sleep disturbance in PTSD. |
| Q36557741 | Pharmacotherapeutic treatment of nightmares and insomnia in posttraumatic stress disorder: an overview of the literature |
| Q35752941 | Pharmacotherapy for Post-traumatic Stress Disorder In Combat Veterans: Focus on Antidepressants and Atypical Antipsychotic Agents |
| Q24244802 | Pharmacotherapy for post traumatic stress disorder (PTSD) |
| Q22255551 | Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis |
| Q33988963 | Pharmacotherapy for posttraumatic stress disorder: empirical review and clinical recommendations |
| Q36777691 | Pharmacotherapy in post-traumatic stress disorder: evidence from randomized controlled trials |
| Q36829455 | Pharmacotherapy of PTSD: Current Status and Controversies |
| Q30479154 | Pharmacotherapy of PTSD: premises, principles, and priorities |
| Q35686859 | Pharmacotherapy of anxiety disorders: a critical review |
| Q35011794 | Pharmacotherapy of anxious disorders |
| Q36311034 | Pharmacotherapy of comorbid mood, anxiety, and substance use disorders |
| Q36106785 | Pharmacotherapy of post-traumatic stress disorder: a family practitioners guide to management of the disease |
| Q36147707 | Pharmacotherapy of treatment-resistant combat-related posttraumatic stress disorder with psychotic features |
| Q84478566 | Post-traumatic stress disorder |
| Q34418655 | Post-traumatic stress disorder and acute stress disorder I: their nature and assessment considerations. |
| Q35003793 | Post-traumatic stress disorder in women: current concepts and treatments |
| Q36133824 | Post-traumatic stress disorder in women: epidemiological and treatment issues |
| Q34487670 | Post-traumatic stress disorder: a review of psychobiology and pharmacotherapy. |
| Q36909270 | Post-traumatic stress disorder: an evaluation of existing pharmacotherapies and new strategies |
| Q34359824 | Posttraumatic Stress Disorder and Acute Stress Disorder II: Considerations for Treatment and Prevention |
| Q37353639 | Posttraumatic stress disorder and stress-related disorders |
| Q36415265 | Posttraumatic stress disorder in medically ill patients: what is known, what needs to be determined, and why is it important? |
| Q35947312 | Posttraumatic stress disorder in patients with bipolar disorder: a review of prevalence, correlates, and treatment strategies |
| Q36415279 | Posttraumatic stress disorder: a missed link between psychiatric and cardiovascular morbidity? |
| Q35620802 | Providing a treatment rationale for PTSD: does what we say matter? |
| Q48651003 | Psychiatric consequences of motor vehicle accidents |
| Q37625940 | Psychopharmacological issues in the treatment of TBI and PTSD. |
| Q34977242 | Psychopharmacological treatment in PTSD: a critical review |
| Q24657148 | Psychopharmacotherapy of posttraumatic stress disorder |
| Q36361676 | Responding to the need for sleep among survivors of interpersonal violence: A randomized controlled trial of a cognitive-behavioral insomnia intervention followed by PTSD treatment |
| Q34974832 | Review of sertraline in post-traumatic stress disorder |
| Q35669835 | SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations |
| Q92205894 | Sertraline as a treatment for PTSD: a systematic review and meta-analysis |
| Q46381531 | Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder |
| Q44400981 | Sertraline is more effective than imipramine in the treatment of non-melancholic depression: results from a multicentre, randomized study |
| Q34126472 | Serum brain-derived neurotrophic factor predicts responses to escitalopram in chronic posttraumatic stress disorder |
| Q30410039 | Sleep and REM sleep disturbance in the pathophysiology of PTSD: the role of extinction memory |
| Q36298093 | Sleep disturbances and PTSD: a perpetual circle? |
| Q36519341 | Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management |
| Q36798519 | Sleep-specific mechanisms underlying posttraumatic stress disorder: integrative review and neurobiological hypotheses |
| Q36191978 | Social, psychological, and psychiatric interventions following terrorist attacks: recommendations for practice and research |
| Q42618250 | Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial |
| Q37871044 | Spectrum of anxiety disorders: diagnosis and pharmacologic treatment |
| Q37595431 | Sudden gains in prolonged exposure and sertraline for chronic PTSD. |
| Q41978624 | Symptoms of anxiety, depression, and posttraumatic stress among survivors of the 2005 Pakistani earthquake |
| Q24682953 | The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care |
| Q35630395 | The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding |
| Q34651514 | The effectiveness of mirtazapine in the treatment of post-traumatic stress disorder: a 24-week continuation therapy |
| Q36458877 | The effects of positive patient testimonials on PTSD treatment choice |
| Q34558808 | The medical benefit of 5-HT research |
| Q35124352 | The psychological impact of maxillofacial trauma: An overview of reactions to trauma |
| Q34466155 | The psychopharmacologic treatment of depression and anxiety in the context of chronic pain |
| Q28236713 | The role of atypical antipsychotics in bipolar depression and anxiety disorders |
| Q40430141 | The role of coercion in the treatment of women with co-occurring disorders and histories of abuse |
| Q35208413 | The safety of SSRIs in generalised anxiety disorder: any reason to be anxious? |
| Q39269522 | Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment |
| Q35043908 | To breathe, perchance to sleep: sleep-disordered breathing and chronic insomnia among trauma survivors |
| Q27026926 | Translational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorder |
| Q38580554 | Treatment goals: response and nonresponse |
| Q37532398 | Treatment of Post-Traumatic Stress Disorder Nightmares at a Veterans Affairs Medical Center |
| Q38901939 | Treatment of Post-Traumatic Stress Disorders with the Alpha-1 Adrenergic Antagonist Prazosin |
| Q38430456 | Treatment of Sleep Disturbances in Post-Traumatic Stress Disorder: A Review of the Literature |
| Q35901891 | Treatment-resistant posttraumatic stress disorder: strategies for intervention |
| Q27311209 | Understanding and meeting information needs for patients with posttraumatic stress disorder |
| Q35631836 | Up-regulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioural deficits in a putative mouse model of post-traumatic stress disorder |
| Q35651404 | WCA Recommendations for the long-term treatment of posttraumatic stress disorder. |
| Q44758781 | WCA recommendations for the long-term treatment of anxiety disorders. |
| Q35603068 | What would you choose? Sertraline or prolonged exposure in community and PTSD treatment seeking women |
| Q35620811 | What you believe is what you want: modeling PTSD-related treatment preferences for sertraline or prolonged exposure |
| Q22305681 | World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders |
| Q81073205 | [Simple and complex post-traumatic stress disorders. Diagnostic and therapeutic approaches] |
Search more.